Share This Page
Drug Price Trends for NDC 17478-0605
✉ Email this page to a colleague
Average Pharmacy Cost for 17478-0605
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 17478-0605
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| COSOPT | Thea Pharma, Inc. | 17478-0605-10 | 10ML | 63.86 | 6.38600 | 2023-02-01 - 2028-01-31 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 17478-0605
Introduction
The drug identified by NDC 17478-0605 is a critical pharmaceutical product subjected to market dynamics influenced by regulatory, competitive, and economic factors. Given the increasing complexity of pharmaceutical supply chains and evolving pricing landscapes, a comprehensive market analysis and precise price projections are essential for stakeholders including manufacturers, healthcare providers, and investors.
Product Overview
NDC 17478-0605 corresponds to a specialty medication classified within the therapeutic category (insert specific therapeutic class if available). Its formulation, approved indications, and patent status significantly influence market penetration and pricing strategies.
Note: For accurate analysis, detailed product data including label claims and patent duration should be integrated when available.
Market Landscape
1. Market Size and Growth Trajectory
Recent industry reports project a CAGR of (insert percentage) for the specialty drug segment over the next five years. This growth is fueled by rising prevalence of (related indications), advances in targeted therapies, and increasing adoption of biologics and biosimilars.
Specifically, for NDC 17478-0605, assuming it addresses (specific disease/condition), the market size can be estimated using epidemiological data:
- Prevalence Rate: (Insert data)
- Treatment Rate: (Insert data)
- Patient Population: (Calculate based on above)
Total market size currently stands at approximately (insert dollar amount), with an anticipated growth driven by (specific factors like aging populations, unmet medical needs).
2. Competitive Environment
The competitive landscape includes:
- Patented molecules/biologics: (List key competitors, if any)
- Biosimilars/generic alternatives: Entry timelines and pricing impact
- Regulatory pathways: Approved or pending applications influence market entry speed
Patent expirations or exclusivity periods greatly impact pricing and market share; for example, a patent expiration in (year) could lead to numerous biosimilar entrants, exerting downward price pressure.
3. Regulatory and Reimbursement Factors
Pricing is heavily affected by reimbursement policies, insurance coverage, and government price controls. Notably:
- Medicaid/Medicare policies influencing allowable payment thresholds
- Value-based pricing initiatives tied to demonstrated clinical outcomes
Any recent regulatory shifts, such as accelerated approvals or value-based contracts, modulate pricing strategies.
Historical Pricing and Cost Dynamics
Historical data suggests that niche biologics and specialty medicines have experienced significant price increases due to R&D investments and limited competition. The average launch price for biologics ranges from $XX,XXX to $XXX,XXX annually, depending on indication and treatment regimen.
Cost Drivers:
- Manufacturing complexities, particularly for biologics
- High R&D and clinical trial expenditures
- Supply chain costs and storage requirements
Price erosion typically occurs post-patent expiry or with biosimilar market entry, leading to a reduction of 20-40% in net prices.
Price Projection Analysis
1. Short-Term (1-3 years)
Assuming current exclusivity status, the drug is likely to sustain or slightly increase its price, influenced by:
- Inflationary pressures
- Increased demand due to expanded indications
- Limited biosimilar competition (if patent protected)
Projected annual list price: $XX,XXX to $XX,XXX
2. Mid-Term (3-5 years)
Potential patent expiration or biosimilar entry may commence, leading to:
- Price reductions of up to 25-40%
- Increased market penetration
- Shift toward value-based contracting driving discounts
Remaining competitive pricing will likely hover around $XX,XXX, contingent on biosimilar adoption rates and payer negotiations.
3. Long-Term (Beyond 5 years)
If biosimilar competition becomes dominant, prices could stabilize at approximately $X,XXX to $X,XXX per treatment course, reflecting substantial market saturation and improved manufacturing efficiencies. Entry of next-generation therapies could further influence price trajectories.
Financial and Strategic Implications
Stakeholders should consider:
- Investing in biosimilar development to capitalize on imminent patent cliffs
- Negotiating value-based agreements preemptively
- Monitoring regulatory updates for accelerated pathways or exclusivity extensions
The potential for price erosion underscores the importance of strategic planning in inventory, R&D investment, and market positioning.
Risks and Uncertainties
- Regulatory delays or denials could postpone market entry or expansion.
- Competitive biosimilar entry might accelerate price declines.
- Changes in healthcare policy could impose price caps or reimbursement adjustments.
- Patent litigation outcomes may extend exclusivity or lead to generic entry.
Conclusion
NDC 17478-0605 operates within a rapidly evolving pharmaceutical market characterized by high growth potential but also significant competitive and regulatory uncertainties. While current pricing maintains premium levels due to patent exclusivity and manufacturing complexity, impending biosimilar competition and policy shifts are projected to exert downward pressure in subsequent years.
Strategic stakeholders should navigate these dynamics by leveraging patent protections, engaging in value-based contracting, and preparing for increased biosimilar penetration to optimize financial returns and market share.
Key Takeaways
- The current market for NDC 17478-0605 is supported by patent exclusivity, with prices estimated between $XX,XXX and $XX,XXX annually.
- Patent expiration proceedings and biosimilar entrants forecast a gradual price reduction, potentially up to 40% over five years.
- Manufacturers should proactively develop biosimilar pipelines and negotiate value-based contracts to mitigate revenue erosion.
- Regulatory and reimbursement policies remain pivotal; policy shifts could either bolster or diminish profit margins.
- Continuous market monitoring and adaptive pricing strategies are crucial for maximizing long-term value.
FAQs
1. When is the patent expiry for NDC 17478-0605, and what impact does it have on pricing?
Patent expiry is projected for (year), after which biosimilar entry is expected, likely reducing prices by 25-40% due to increased competition.
2. What are the key factors influencing the price of this drug over the next five years?
Patent status, biosimilar market entry, reimbursement policies, clinical demand, and manufacturing costs primarily influence pricing trajectories.
3. How can manufacturers prepare for biosimilar competition?
By investing in biosimilar development, establishing strategic partnerships, and engaging with payers early to secure formulary access.
4. What role do regulatory agencies play in shaping the market?
Regulatory approval processes, accelerated pathways, and patent litigations directly impact market entry timelines and pricing strategies.
5. Are there any upcoming policy reforms likely to affect the drug’s pricing?
Potential reforms include stricter price controls and value-based payment models, which could influence reimbursement rates and net prices.
References
- (Insert industry report or reference about specialty drug market trends)
- (Insert regulatory agency publication regarding biologics and biosimilars)
- (Insert pricing studies or market data sources)
- (Insert patent law updates relevant to biologics)
- (Insert healthcare policy analyses on drug pricing reforms)
Note: Specific references should be added based on the most recent and authoritative industry data for accuracy.
More… ↓
